SCHEMBL3016601

SCHEMBL3016601

CCOC(=O)C1C(C(=O)OCC)N2CCN1CC2

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.46
ALDH1A1 P00352 7/20 0.43
GAA P10253 2/20 0.40
TSHR P16473 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
PPM1B O75688 1/20 0.39
PTPN1 P18031 1/20 0.39
PPP1CC P36873 1/20 0.39
LMNA P02545 1/20 0.39
HSD17B10 Q99714 1/20 0.39
POLB P06746 1/20 0.38
HTT P42858 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1615657 0.84 MAPT (0.45) MAPTALDH1A1GAACYP3A4CYP2D6
SCHEMBL3019089 0.80 MAPT (0.36) MAPTALDH1A1LMNAHSD17B10POLB
SCHEMBL3454065 0.78 ALDH1A1 (0.42) MAPTALDH1A1TSHRCYP2C19POLB
SCHEMBL3013693 0.77 MAPT (0.42) MAPTALDH1A1GAAHSD17B10SMN1; SMN2
SCHEMBL3012161 0.77 MAPT (0.42) MAPTALDH1A1GAAHSD17B10SMN1; SMN2
SCHEMBL3017836 0.77 MAPT (0.42) MAPTALDH1A1GAATSHRCYP3A4
SCHEMBL15355170 0.74 MAPT (0.40) MAPTALDH1A1LMNASMN1; SMN2
SCHEMBL765596 0.74 MAPT (0.40) MAPTALDH1A1LMNASMN1; SMN2
SCHEMBL12123892 0.72 MAPT (0.42) MAPTALDH1A1GAACYP3A4CYP2D6
SCHEMBL31196774 0.72 MAPT (0.42) MAPTALDH1A1GAACYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100204438-A1 METHOD FOR PRODUCING TEDA DERIVATIVES BASF SE (DE) 2010-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100204438-A1 METHOD FOR PRODUCING TEDA DERIVATIVES TES, TRRAP, NAAA MAPT 1647/4885ALDH1A1 720/4885GAA 3017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.